Prevention of respiratory syncytial virus infection in infants
- 29 April 2004
- Vol. 328 (7447), 1026-1027
- https://doi.org/10.1136/bmj.328.7447.1026
Abstract
Acknowledgments Many thanks to Nichola Goddard, Communicable Disease Surveillance Centre, Health Protection Agency, Colindale, London, for providing the epidemiological data regarding respiratory syncytial virus.This publication has 10 references indexed in Scilit:
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- The reducing incidence of respiratory tract infection and its relation to antibiotic prescribing.2003
- Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSVJournal of General Virology, 2003
- Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant womenVaccine, 2003
- Clinical experience with respiratory syncytial virus vaccinesThe Pediatric Infectious Disease Journal, 2003
- Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995–March 1998Epidemiology and Infection, 2002
- Basic epidemiology and immunopathology of RSV in childrenPaediatric Respiratory Reviews, 2000
- Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.1998
- Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) A meeting report of the WHO Programme for Vaccine DevelopmentVaccine, 1995
- RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12American Journal of Epidemiology, 1969